A Phase 1, First-in-Human, Investigator-Initiated, Open-label Study to Assess the Safety, Feasibility, Cytokinetics, and Preliminary Antitumor Activity of GC511B in Adult Subjects With DLL3+ Relapsed/Refractory Small Cell Lung Cancer
Latest Information Update: 03 Dec 2025
At a glance
- Drugs GC 511B (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
Most Recent Events
- 03 Dec 2025 New trial record